Enter Note Done
Go to previous page in this tab
Session
  • Presentation | ASH-FDA Joint Symposium I - Redefining Red Cell Therapies - New Directions in Classical Hematology
  • Special-Interest Sessions and Studios
  • Bookmark Icon
  • Mitapivat to Treat Anemia in Adults with Alpha- or Beta-Thalassemia
  • Schedule
    Notes
  • Location IconMCCNO - 343-345
    Set Timezone
  •  
    Route Me

Generic 'disconnected' Message
Special-Interest Sessions



Disclosure:
No relevant conflicts of interest to declare.

These joint sessions, co-sponsored by the U.S.
Food and Drug Administration (FDA), will feature therapies recently approved to
treat hematologic disorders. FDA product-reviewers will discuss the safety and
efficacy issues for the products' clinical trials and toxicity studies. The
program will also include clinicians who will discuss their perspectives on the
use of the products in the real-world setting. There will be ample time for
questions from the audience.More to come...
CME Status
Program
Main Session